Arthritis Advisory Committee Meeting
Committee Meeting May 9, 2012 8:00 a.m. to 5:00 p.m. (Day 2 of 2)
Agenda: On May 9, 2012, the committee will discuss new drug application (NDA) 203214, tofacitinib tablets, Pfizer Inc., for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment